Inulin
Inulin (Prebiotic Fiber)
A prebiotic soluble fiber that feeds beneficial gut bacteria, supports digestive health, and may improve blood sugar and mineral absorption.
Inulin is a type of soluble fiber found in many plants, particularly chicory root. It's classified as a prebiotic because it selectively feeds beneficial gut bacteria like Bifidobacteria and Lactobacilli. Fermentation of inulin produces short-chain fatty acids that support gut health, immunity, and metabolic function. It also improves calcium absorption and may help with blood sugar control and appetite regulation.
Mechanisms of Action
Prebiotic Effect
Selectively feeds beneficial bacteria
SCFA Production
Fermented to produce short-chain fatty acids
Mineral Absorption
Enhances calcium and magnesium uptake
Recommended Dose
5-15g daily
Loading: Start with 3-5g and gradually increase over 1-2 weeks to minimize GI upset
Optimal Timing
- With meals or in beverages
- Can be taken any time of day
- Divide into multiple doses if taking higher amounts
Take with food
Best Form
Chicory root inulin powder
Alternatives: Inulin capsules, Inulin-FOS blend
Powder is most economical and easy to mix. Chicory root is the most common source. Often combined with FOS.
Duration
Minimum: 4 weeks
Optimal: 12 weeks
Cycling: Not required
Note: Dissolves easily in water and beverages. Start low and increase slowly to allow gut adaptation.
Personalized Dosage Calculator
Get a dosage recommendation tailored to your body weight, age, goals, and health profile.
Set up your health profile for personalized recommendations
Improved Gut Health
Increased beneficial bacteria populations
Improved Regularity
Better bowel movement frequency and consistency
Appetite Control
Increased satiety and reduced hunger
Gas & Bloating
Common initial side effect as gut adapts
May worsen symptoms in FODMAP-sensitive individuals; start very low
Who Should NOT Take This
- FODMAP sensitivity (may worsen symptoms)
- SIBO (small intestinal bacterial overgrowth)
Drug Interactions
High fiber may slightly affect absorption timing of some medications
May enhance blood sugar lowering; monitor if diabetic
Possible Side Effects
Tip: Start low (3-5g) and increase gradually over weeks
Tip: Reduce dose; increase slowly
Warnings
- Start with low doses to avoid GI discomfort
- Not suitable for those following strict low-FODMAP diet
- May exacerbate SIBO symptoms
Top studies from 40+ peer-reviewed papers
Talukdar JR et al. โข The American journal of clinical nutrition (2024)
โITF may reduce low-density lipoprotein, triglycerides, and body weight.โ
Key Findings:
- ITF may reduce low-density lipoprotein, triglycerides, and body weight.
- However, due to low to very low CoE, further well-designed and executed trials are needed to confirm these effects.
- Further research warranted to confirm findings
Reimer RA et al. โข The American journal of clinical nutrition (2024)
โChicory ITF supplementation may benefit weight management by reducing body weight, BMI, fat mass, waist circumference, and, to a certain extent, body fat percentage.โ
Key Findings:
- Chicory ITF significantly reduced body weight [mean difference (MD): -0.97 kg; 95% CI: -1.34, -0.59); n = 1184] compared with placebo.
- Except for considerable heterogeneity in body weight (I2: 73%) and body fat percentage (I2: 75%), all other outcomes had negligible to moderate heterogeneity.
- Significant reduction in body weight, BMI, and waist circumference was evident irrespective of participants' health status.
Wallace C et al. โข The Cochrane database of systematic reviews (2023)
โThe results from this review demonstrate that probiotics and synbiotics may be more efficacious than placebo in achieving treatment success, but the evidence is of low certainty.โ
Key Findings:
- Meta-analysis showed no difference in withdrawals due to adverse events between probiotics (1/275) and placebo (1/269) (RR 1.00, 95% CI 0.07 to 15.12).
- Synbiotics may result in more treatment success at study end when compared with placebo, with 47% success in the probiotic group versus 35% success in the placebo group (RR 1.34, 95% CI 1.03 to 1.74; 310 participants; 4 studies; I2 = 0%; low certainty).
- Meta-analysis showed little to no difference in withdrawals due to adverse events between synbiotics (8/155) and placebo (1/147) (RR 4.58, 95% CI 0.80 to 26.19), or in any reported adverse events (3/96 versus 1/93, RR 2.88, 95% CI 0.32 to 25.92).
Juhรกsz AE et al. โข The American journal of clinical nutrition (2023)
โGalactomannans were the most effective dietary fiber for reducing the levels of HbA1c, fasting blood glucose, triglycerides, and LDL cholesterol in patients with type 2 diabetes.โ
Key Findings:
- Galactomannans had the highest effect on reducing the levels of HbA1c (SUCRA: 92.33%) and fasting blood glucose (SUCRA: 85.92%).
- With regard to fasting insulin level, HOMA-IR, ฮฒ-glucans (SUCRA: 73.45%), and psyllium (SUCRA: 96.67%) were the most effective interventions.
- Galactomannans were ranked first in reducing the levels of triglycerides (SUCRA: 82.77%) and LDL cholesterol (SUCRA: 86.56%).
- With regard to cholesterol and HDL cholesterol levels, xylo-oligosaccharides (SUCRA: 84.59%) and gum arabic (SUCRA: 89.06%) were the most effective fibers.
Yang J et al. โข The Journal of clinical investigation (2024)
โPrebiotics have the potential to modify the gut microbiota and metabolome, resulting in improved frailty status and prevention of its occurrence.TRIAL REGISTRATIONClinicalTrials.gov NCT03995342.โ
Key Findings:
- Body composition, commonly used scales, biochemical markers, intestinal microbiota, and metabolites were examined in 3 groups of older individuals (nonfrail, prefrail, and frail).
- Additionally, it stimulated an elevation in gut probiotic count and induced alterations in microbial metabolite expression levels as well as corresponding metabolic pathways.CONCLUSIONSThe findings suggest a potential link between changes in the gut microbiota and frailty in older adults.
- Prebiotics have the potential to modify the gut microbiota and metabolome, resulting in improved frailty status and prevention of its occurrence.TRIAL REGISTRATIONClinicalTrials.gov NCT03995342.
Study Type Distribution
Goals This Supplement Supports
Related Goals
This information is for educational purposes only and is not intended as medical advice. Always consult a qualified healthcare provider before starting any supplement.